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Abstract
While performance since the introduction of the JACIE quality management system has been shown to be improved for
allogeneic hematopoietic stem cell transplants (HSCT), impact on autologous-HSCT remains unclear in Europe. Our study
on 2697 autologous-HSCT performed in adults in 17 Belgian centres (2007–2013) aims at comparing the adjusted 1 and 3-yr
survival between the different centres & investigating the impact of 3 centre-related factors on performance (time between
JACIE accreditation achievement by the centre and the considered transplant, centre activity volume and type of HSCT
performed by centres: exclusively autologous vs both autologous & allogeneic). We showed a relatively homogeneous
performance between Belgian centres before national completeness of JACIE implementation. The 3 centre-related factors
had a signiﬁcant impact on the 1-yr survival, while activity volume and type of HSCT impacted the 3-yr survival of
autologous-HSCT patients in univariable analyses. Only activity volume (impact on 1-yr survival only) and type of HSCT
(impact on 1 and 3-yr survivals) remained signiﬁcant in multivariable analysis. This is explained by the strong relationship
between these 3 variables. An extended transplantation experience, i.e., performing both auto & allo-HSCT, appears to be a
newly informative quality indicator potentially conveying a multitude of underlying complex factors.
Introduction
Hematopoietic stem cell transplantation (HSCT) following
high-dose chemotherapy with or without radiotherapy is
widely used for the treatment of malignant and non-malignant
diseases [1–4]. Over the years, a better control of the different
transplant-related toxicities reduced post-transplant morbidity
and mortality. Given the balance between pros and cons,
autologous-HSCT (auto-HSCT) are mostly performed for the
treatment of lymphomas, plasma cell disorders and certain
solid tumours, and allogeneic transplants (allo-HSCT) mainly
for acute leukemias, myelodysplastic syndromes and myelo-
proliferative neoplasms, as well as a number of non-malignant
disorders [5–9]. The advantages of autologous over allogeneic
transplants (allo-HSCT) are the lower risk of life-threatening
complications, such as graft-versus-host disease, graft failure
and infections. Moreover, treatment-related mortality (TRM)
is lower and auto-HSCT are relatively well tolerated by
elderly patients [10–13]. However, the use of a patient’s own
stem cells has certain disadvantages. The autograft may be
contaminated with tumour cells and patients do not beneﬁt
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from the potent immune-mediated graft-versus-tumour effect
as observed after allo-HSCT, explaining the higher relapse
rate after auto-compared to allo-HSCT [6, 10, 11, 14].
Quality management organizations were launched end of
the 1990’s, FACT (Foundation for the Accreditation of Cell
Therapy) in the USA followed by JACIE (Joint Accred-
itation Committee-ISCT [International Society for Cellular
Therapy] & the EBMT [European Society for Blood and
Marrow Transplantation]) in Europe (https://www.ebmt.
org/jacie-accreditation) to improve the quality of HSCT
[15]. While increasing evidence suggests that patient out-
come has been improved for allo-HSCT since the intro-
duction of the JACIE quality management system (QMS)
[16–18], results remain contradictory for auto-HSCT in
Europe. A preliminary retrospective observational study
showed a signiﬁcant improvement in relapse-free survival
when the centre was further along in the JACIE accredita-
tion process [16]. However, these ﬁndings were no longer
observed with 5 more follow-up years of the same EBMT
cohort (66 281 auto-HSCT between 1999 and 2007) [1].
In Belgium, all centres performing HSCT needed to
achieve JACIE accreditation by the end of 2017 to get
reimbursement [19]. The Belgian Cancer Registry (BCR)
has a lot of expertise in collecting, handling, quality con-
trolling, coding, analysing and reporting on cancer-related
public health data [20]. Thanks to collaboration between the
BCR and the Belgian Haematology Society (BHS), it was
decided in 2012 to maintain a Belgian Transplant Registry
(BTR) at the BCR. The initial data are downloaded from the
EBMT-ProMISe database and handled by the joint effort
BCR-BHS. The BTR is a good starting point for reporting
transplant centre-speciﬁc survival rates after HSCT as
already required in other countries, such as the USA, in the
frame of QMS.
The present study aims at comparing adjusted survival
between the different auto-HSCT centres and investigating




Data on all HSCT performed in Belgium between 2007 and
2013 were obtained through a download of the full Minimal
Essential Data (MED-A) which are directly introduced by
each participating Belgian centre into the ProMISe data-
base. The downloaded ﬁle was checked and centres were
asked to correct contradictory results and to ﬁll out missing
variables. The national social security identity number for
each patient was requested to obtain the vital status for
outcome analysis. If needed, a data-manager collected the
data on-site.
Vital status and date of death/censoring
As the BCR is enabled by law to retrieve vital statuses by
coupling its database to the national Crossroads Bank for
Social Security, vital statuses were obtained for the BTR
database entries. Follow-up was collected until 31 Decem-
ber 2015. Patients alive at the follow-up end are censored at
the end of follow-up and patients who are lost to follow-up
are censored at earlier dates. The unit of analysis in the
study was the transplant, therefore patients could participate
more than once if they received several transplants. For
those cases, the vital status of the patient was only used for
the last transplant. Other transplants are censored at the date
the next transplant takes place. In total, 15% of patients in
the complete database (both auto and allo-HSCT) have
more than one transplant.
Exclusion criteria
A total of 2979 auto-HSCT from 22 Belgian centres were
registered over the 2007-2013 period. Our target population
for all survival analysis was adult patients undergoing auto-
HSCT for hematological disorders. Patients younger than
16 years (n= 121) and transplants for solid tumours were
excluded (n= 77). Centres that performed less than 5 auto-
HSCT per year on average were excluded (n= 79 trans-
plants from 3 centres), according to the FACT-JACIE
standards [15]. Finally, 5 records had a missing vital status,
resulting in a total of 2697 auto-HSCT records for outcome
analyses from 17 Belgian centres.
Observed survival
The observed survival rates are reported at one year and
3 years after transplant with a minimal follow-up of at least
2 years. Observed survival was calculated with the Kaplan–
Meier method using a semi-complete cohort analysis
approach.
Adjusted survival
Variables used in the multivariable models
● Transplant year over the 2007–2013 period.
● Age of the patient at transplant divided into 4 categories:
16–19 years, 20–39 years, 40-59 years and ≥60 years.
● Gender of the patient: male versus female.
● Performance status before transplant assessed with the
Karnosfky scale: 2 main categories were considered,
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90–100 (well performing patients) versus 0–80 (less
well performing patients).
● Disease risk index (DRI) adapted from [21], which is a
4-level grouping scheme (low, intermediate, high and
very high) combining three major prognostic factors for
HSCT outcome: diagnosis, disease status and genetic
aberrations. The genetic risk groups are only deﬁned for
patients with the diagnosis of acute myeloid leukemia
(adapted from the ELN stratiﬁcation [22, 23]) and
myelodysplastic syndrome (adapted from the IPSS score
[24]).
● Transplant number: all transplants of patients who
received multiple HSCT (autologous and/or allogeneic)
were ordered in time and given a transplant number
accordingly.
● Time between diagnosis of the disease and auto-HSCT:
2 categories were considered, <18 and ≥18 months.
Generalized linear regression model (GRp model)
In order to fairly compare survival estimates across the
different Belgian transplant centres, the overall survival
rates were adjusted for the different confounders as
mentioned above. This was done by applying a ﬁxed
effects censored data generalized linear regression model
[25, 26] [Supplementary Data]. Separate models were
applied to 1 and 3-year survivals. All relevant covariables
were entered into the GRp model and a backward elim-
ination procedure based on Akaike’s information criterion
(AICc) [27] was used to deﬁne the list of covariables that
most strongly predicted 1 or 3-year survival. Transplant
year, Karnofsky performance status, DRI and the total
number of performed transplants were retained for 1-year
survival by the AICc selection. In addition to these 4
variables, age of the patient at transplant and time between
diagnosis and transplant were selected for the endpoint of
3-year survival.
Once the models were built, accurate predicted survival
rates based on the centres’ case-mix were obtained. The
centre was not included as a confounder in the analysis but
the centre effect was indirectly assessed. As such it assumes
that the Belgian transplant recipients are dying at the same
uniform rate across all transplant centres, after adjusting for
the main prognostic covariables (i.e., the case-mix). Sub-
sequently, conﬁdence limits for the centre-speciﬁc predicted
survival estimate are calculated by a bootstrapping metho-
dology [28]. We state that when the observed survival lies
outside of the bootstrap-predicted 95% intervals, the
centre 7is over or under-performing the overall network of
centres [28]. These results are summarized by forest plots
(Figs. 1a, b) for all centres.
Odds ratio
Another goal of this study was to assess the impact of three
centre-related factors on the performance of the auto-HSCT
centres:
● Centre activity volume: annual number of auto-HSCT
performed by each centre (continuous variable).
● Type of transplant performed by each centre: centres
that exclusively perform auto-HSCT, vs centres that
perform both auto and allo-HSCT. Centres performing
at least 35 allo-transplants over the whole period were
deﬁned as 'both auto and allo-HSCT', while those
providing less than 5 allo-HSCT per year on average
were labelled 'only auto-HSCT' centres.
● JACIE accreditation time during the 2007–2013 period:
modelled as a continuous variable corresponding to the
time between JACIE accreditation achievement by the
centre and the considered transplant. The value of a
transplant which is performed in an unaccredited centre
at the time of transplant is 0. Ten centres achieved
JACIE accreditation during the period (2008: 1, 2009: 1,
2010: 1, 2011: 1, 2012: 4 & 2013: 2).
These centre-related variables were added to the GRp
models. This enabled us to explore their effect while
adjusting for the other, patient and transplant-related con-
founders that were already found to inﬂuence survival. As
the continuous centre activity volume and JACIE accred-
itation time were found to have a linear relationship with 1
and 3-yr survival, centre volume was divided by 50 and
JACIE time by 365.241 so that every unit increase would
actually correspond to an increase of 50 transplants
(volume) and 1 year (JACIE). No interactions were inclu-
ded in the ﬁnal model because no interactions for a selection
of variables (backward type) remained in the 1-yr survival
model, and only interaction between the centre activity
volume and the centre type in the 3-yr survival model.
However, the interpretation of this interaction is difﬁcult as
the centre activity volume variable is not signiﬁcant.
Results
Diagnostic indications for transplant
Diagnostic indications are listed in Table 1 for the 2,858
auto-HSCT performed in adult patients. As expected, the
most frequent indications are plasma cell disorders, mainly
multiple myelomas (46.5%), and non-Hodgkin’s lympho-
mas (40.2%). No trend modiﬁcation appears over the 2007–
2013 period.
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Outcome analysis
Descriptive analysis
Table 2 shows the variables selected for the multivariable
analysis on the 2697 auto-HSCT. Most transplants were
performed in patients between 40 and 59 years of age
(49.2%) and within 18 months after diagnosis (71.6%). In
66.6% of the transplants, the patients had an intermediate
DRI index. Nearly 90% were ﬁrst auto-HSCT and 9.6%
were second transplants.
Adjusted survival
Observed survival was 88 and 77% at 1 and 3 years,
respectively. The overall adjusted survival for the whole of
Belgium was 89% at 1 year and 78% at 3 years. For 1-yr
survival, 2 out of the 17 centres were found to be over-
performing the general network of Belgian auto-transplant
centres versus 3 underperforming centre (Fig. 1a). For 3-yr
survival, 2 centres were overperforming and 1 under-
performing (Fig. 1b).
Impact of centre-related indicators
The impact of three additional factors on the 1-yr and 3-yr
survival was investigated (Fig. 2): the JACIE accreditation
time of the transplant, the type of transplant performed by
the centre and the centre activity volume. Univariable
analysis showed that each of the 3 variables had a sig-
niﬁcant impact on 1-yr and centre volume and type of
transplant on 3-yr survival (only a trend for JACIE
accreditation time). However, when the 3 variables were
added simultaneously in the adjusted model, (i) the JACIE
accreditation time of centres had no signiﬁcant impact on
1-yr or 3-yr adjusted survivals; (ii) increasing centre activity
volume signiﬁcantly improved survival at 1 year (p=
0.0022) but not at 3 year (p= 0.5341); (iii) performing both
auto- and allo-HSCT had a signiﬁcant positive impact on
both 1-year (p= 0.0349) and 3-year survival (p < 0.0001)
(Fig. 2).
The 3 centre-related indicators are related when taken 2
by 2. The Spearman correlation conﬁrmed the positive
relationship between the centre activity volume and JACIE
accreditation time (0.20199, p < 0.0001). Centres that
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Fig. 1 Forest plot of the survival at 1 year (a) and 3 years (b) for
autologous transplants in Belgium (2007-2013), as predicted by the
multivariable model for all centres. Survival at 1 year was adjusted for
transplant year, performance status, disease risk index and transplant
number. Survival at 3 years was adjusted for transplant year, age,
performance status, time between diagnosis and transplant, disease risk
index and transplant number. Centres are represented by a blue square
that indicates the 1-year (or 3-year) survival for that centre as predicted
by the multivariable model (adjusted for case-mix). 95% conﬁdence
limits for predicted survival are indicated by black lines. The observed
survival for that centre is represented on the forest plot by a dot. The
overall result of predicted survival is indicated by a diamond on the top
of the forest plot. If the actual observed survival of the centre, as
represented by the dot, is higher or lower than the upper or lower limit
of the conﬁdence interval, there is evidence of the centre over-
performing or under-performing, respectively, the overall network of
Belgian centres. Note that centres are not displayed in a particular
order (e.g., by centre activity volume) in order to preserve anonymity
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perform both autologous and allo-HSCT tend to have a
higher activity volume than centres that exclusively perform
auto-HSCT (median number of transplants: 158 versus 104,
p= 0.072). Finally, only one out of 6 centres that exclu-
sively perform auto-HSCT achieved JACIE accreditation
compared to 9 out of 11 centres that perform both auto-
logous and allo-HSCT.
Discussion
The aim of this study was to describe patient- and
transplant-related covariables inﬂuencing short (1-year) and
longer term (3-year) survival of auto-HSCT recipients in
Belgium. Survival within the ﬁrst year is considered as a
better measure of the toxicity of the transplant procedure
itself thereby evaluating the speciﬁc transplant performance
of each centre, whereas survival beyond the ﬁrst year may
be more severely impacted by disease relapse (which
depends on the disease status at transplantation and the time
from diagnosis to transplant) [28]. In the FACT-JACIE
standards, the 1-yr survival outcome is used to compare the
performance of the centre to (inter)national outcome data
and JACIE standard B4.7.5 states that 'If expected 1-year
survival outcome is not met, the Clinical Program shall
submit a corrective action plan' [15]. Our study gives the
opportunity for centres to meet this standard and, if neces-
sary, to implement a corrective action plan to improve
outcomes. In our study, the 2 additional covariables retained
for survival at 3 years by the backward selection procedure,
i.e., age at transplantation and time between diagnosis and
transplant, conﬁrm the arguments of Logan et al. [28]. Our
multicentre study had several limitations, i.e., exclusion of
small centres, transplant as the unit of the study instead of
the patient, incomplete case-mix, not including comorbid-
ities, conditioning regimens…). Despite a relatively
homogeneous performance between centres, two of them
were found to be over-performing and three (only one at 3
years) under-performing. We further examined some centre
characteristics potentially contributing to these differences.
QMS, such as JACIE, have been developed to increase
harmonization and standardization of HSCT with the ﬁnal
aim to improve patient care and outcome. The aim of the
JACIE accreditation time variable is to measure the impact
of being in an accreditation process, which results from a
prolonged preparatory work starting several months before
accreditation achievement. JACIE accreditation time
throughout the study period had no effect on short term or
longer term survival. As Belgian centres implemented this
QMS with different timings from 2008, the impact of
Table 1 Diagnostic indications of the total Belgian adult (≥16 yr-old) population per transplant year
2007 2008 2009 2010 2011 2012 2013 2007-2013
Year of transplant N % N % N % N % N % N % N % N %
Overall 395 382 355 393 464 435 434 2858
Diagnostic indications
Plasma cell disorders 211 53.4 178 46.6 154 43.4 204 51.9 236 50.9 222 51.0 231 53.2 1436 50.2
Multiple myeloma 195 165 148 190 220 201 211 1330 46.5
Primary amyloidosis 8 4 3 3 3 11 10 42 1.5
Other plasma cell disordersa 8 9 3 11 13 10 10 64 2.2
Lymphoma 152 38.5 161 42.1 169 47.6 167 42.5 196 42.2 176 40.5 165 380 1186 41.5
Non-Hodgkin lymphoma 116 129 141 144 174 139 132 984 34.4
Hodgkin lymphoma 35 32 28 23 21 36 33 210 7.3
Lymphoma, NOS 1 0 0 0 1 1 0 3 0.1
Acute leukaemia 18 4.6 31 8.1 13 3.7 11 2.8 16 3.4 8 1.8 9 2.1 106 3.7
Others 12 3.0 12 3.2 19 5.3 11 2.8 16 3.5 29 30 6.7 129 4.5
Solid tumour 6 8 12 8 7 19 21 81 2.8
Auto-immune disease 3 1 3 1 4 9 7 28 1.0
MDS/MPN 3 1 0 1 2 1 1 9 0.3
Chronic leukaemia 0 2 2 0 3 0 1 8 0.3
Histiocytic disorders 0 0 2 0 0 0 0 2 0.1
Bone marrow failure 0 0 0 1 0 0 0 1 0.0
Missing 2 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 0.01
For further analysis, 161 transplants were excluded as described in the exclusion criteria of the Patients and Methods section
aother plasma cell disorders include plasmacytoma (solitary plasmacytoma of bone, multiple plasmocytoma), plasma cell leukemia and POEMS
syndrome
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JACIE implementation may be underestimated by the short
periods of accreditation. Gratwohl et al. [16]. did not show a
signiﬁcant impact of JACIE accreditation on long-term
outcome of auto-HSCT (as observed for allografts [16, 29,
30]), but a stepwise improvement in outcome depending on
the particular phase of the accreditation process at the time
of transplant [17]. However, JACIE accreditation status
signiﬁcantly inﬂuenced outcome of auto-HSCT in speciﬁc
indications, such as autoimmune diseases [31].
Several studies showed that overall survival, treatment
failure and TRM were inﬂuenced by centre activity volume
for allo-HSCT, with thresholds for high volume centre
varying from 3 to 45 transplants per year [32–38]. Data on
auto-HSCT remain limited [28, 38]. Our study showed that
transplant centre activity volume had a signiﬁcant impact on
survival of auto-transplant patients at 1-year, even after
exclusion of very low volume centres. We excluded such
centres that did not meet a minimal threshold of activity for
statistical reasons. However, this number is also in line with
JACIE standards that require a minimum of 5 auto-
transplant patients on average per year [15].
We also identiﬁed an inﬂuence of the type of transplants
centres perform. Patients transplanted in centres that per-
formed both allo and auto-HSCT had signiﬁcantly higher 1
and 3-year survivals than in centres only performing auto-
HSCT. The three additional centre-related factors, JACIE
accreditation time, type of transplant and activity volume,
are strongly related. It is noteworthy that over-performing
centres had all a mixed allo- and auto-HSCT activity while
under-performing centres were all among centres perform-
ing only auto-HSCT. The JACIE accreditation process may
have ‘forced’ centres to structure and optimize care, which
is easier from a logistic point of view for large centres with
more expertise. So, we believe that any of these three
related factors can be seen as a proxy for centre ‘expertise’.
It is not clear which factor of the three is more important
than the others. The stronger impact of the type of transplant
centre and to a lesser extent of the centre activity volume
compared to achieving JACIE accreditation may be
explained by the fact that the impact of quality management
may be efﬁcient long before accreditation. The type of
transplant centre variable appears to be a newly identiﬁed
and informative indicator which conveys a multitude of
underlying complex factors: it may indicate the usefulness
of a large centre mastering different HSCT techniques and
engaged in a quality system.
A GRp model on pseudo values was applied [25]. This
model has several advantages: instead of modelling the
hazards (e.g., the Cox model), the survival probability is
directly modelled. A direct link between certain factors and
their inﬂuence on survival time can thus be drawn and
easily communicated. Moreover, this method can also be
applied when the proportional hazards assumption does not
hold, which was the case for some of the covariables under
study. Since ‘centre’ is not added to the model, we are
applying an indirect way of standardizing centres. In a large
simulation exercise (data not shown) in which we compared
direct to indirect standardization of centres using the GRp
model, we have found that both have advantages and dis-
advantages. A patient may have received several auto-
HSCT or a combination of both auto- and allo-HSCT dur-
ing the period in which transplants were registered into
Table 2 Case mix of the total Belgian autologous transplant
population (2007–2013): variables considered in the multivariable
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ProMISe (2007-2013), thereby introducing a bias. To
investigate this bias, we repeated all statistical models only
on the patients that contributed one transplant in the BTR.
The ﬁnal results showed little to no difference globally and
on the level of the individual centres. Given these conclu-
sions and the fact that only 15% of patients contribute more
than one transplant, we believe the bias to be minimal.
In conclusion, the results presented here are the ﬁrst on
the Belgian transplant level and the ﬁrst to identify centre
activity as predictor of survival after auto-HSCT. This study
shows relatively homogeneous performance between Bel-
gian centres before complete JACIE accreditation imple-
mentation at the national level. Feedback reports for each
centre with comparison to national and even international
activities may stimulate continuous quality improvement in
the ﬁeld of HSCT [15]. Further studies with a longer period
of accreditation to better assess the survival improvements
of the implementation of a QMS in auto-HSCT are how-
ever, warranted.
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